Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 23.18 | — | 21.64 | 17.64 | 11.42 | 17.77 | 26.94 | 16.26 | 20.96 | 13.30 | — | 17.77 | 10.83 | 23.21 | 25.93 | 16.51 | 10.86 | 16.98 | 1564.47 | 60.51 | 8.52 |
| — | — | -19.7% | +8.4% | -45.5% | +33.6% | — | -8.5% | +93.5% | -42.7% | — | +7.6% | -0.3% | +36.7% | -98.3% | -72.7% | +27.5% | +19.4% | +13165.2% | +411.0% | -84.4% | |
| P/S Ratio | 6.63 | 5.03 | 6.28 | 4.85 | 4.48 | 4.91 | 5.29 | 3.84 | 3.48 | 3.09 | 3.42 | 3.58 | 3.34 | 3.67 | 4.12 | 3.67 | 2.76 | 3.11 | 2.85 | 3.16 | 2.97 |
| — | +2.4% | +18.7% | +26.3% | +28.6% | +59.2% | +54.9% | +7.4% | +4.3% | -16.0% | -17.1% | -2.6% | +21.0% | +18.1% | +44.7% | +16.1% | -7.0% | -10.9% | -10.3% | +28.0% | -2.0% | |
| P/B Ratio | 8.72 | 13.37 | 7.46 | 6.80 | 6.49 | 7.10 | 7.39 | 6.04 | 5.72 | 4.72 | 5.23 | 4.47 | 4.24 | 4.60 | 5.00 | 5.12 | 3.69 | 3.85 | 3.77 | 4.35 | 4.11 |
| — | +88.3% | +0.9% | +12.5% | +13.5% | +50.6% | +41.3% | +35.1% | +35.0% | +2.6% | +4.7% | -12.6% | +14.6% | +19.3% | +32.6% | +17.6% | -10.0% | -12.5% | -12.4% | +8.1% | -10.0% | |
| P/FCF | 20.64 | 10.64 | 18.00 | 12.32 | 8.79 | 48.31 | 21.34 | 10.28 | 6.31 | 17.96 | 10.80 | 13.02 | 14.42 | 11.02 | 16.00 | 11.37 | 7.19 | 11.74 | 11.77 | 7.51 | 7.08 |
| — | -78.0% | -15.6% | +19.8% | +39.3% | +169.1% | +97.5% | -21.0% | -56.3% | +62.9% | -32.5% | +14.5% | +100.7% | -6.1% | +35.9% | +51.3% | +1.6% | +18.9% | +41.2% | -28.9% | -25.6% | |
| EV / EBITDA | 14.70 | — | 14.45 | 11.64 | 9.77 | 12.55 | 13.48 | 10.62 | 19.54 | 7.97 | — | 13.19 | 8.58 | 12.41 | 13.32 | 11.48 | 7.31 | 9.73 | 33.57 | 19.15 | 6.38 |
| — | — | +7.2% | +9.6% | -50.0% | +57.5% | — | -19.5% | +127.8% | -35.8% | — | +14.9% | +17.3% | +27.6% | -60.3% | -40.1% | +14.5% | -4.0% | +319.4% | +138.8% | -37.4% | |
| EV / EBIT | 18.16 | — | 20.13 | 18.34 | 10.06 | 14.81 | 20.70 | 13.83 | 25.83 | 11.62 | — | 15.92 | 11.13 | 16.02 | 20.41 | 14.21 | 9.24 | 14.23 | 281.80 | 28.33 | 7.56 |
| — | — | -2.8% | +32.7% | -61.1% | +27.5% | — | -13.2% | +132.1% | -27.5% | — | +12.0% | +20.4% | +12.5% | -92.8% | -49.8% | +22.2% | +5.3% | +2539.4% | +138.8% | -66.6% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.8% | 79.8% | 79.2% | 79.5% | 79.8% | 78.8% | 76.9% | 79.1% | 79.1% | 77.8% | 76.8% | 70.6% | 77.8% | 78.1% | 77.9% | 81.1% | 80.2% | 77.0% | 78.4% | 63.7% | 83.5% |
| — | +1.2% | +3.0% | +0.5% | +0.8% | +1.3% | +0.1% | +12.0% | +1.7% | -0.5% | -1.5% | -12.9% | -3.0% | +1.5% | -0.6% | +27.3% | -4.0% | -0.9% | -0.5% | -21.5% | +1.1% | |
| Operating Margin | 39.7% | -133.2% | 37.2% | 37.7% | 42.8% | 34.9% | 33.6% | 32.4% | 11.8% | 38.0% | -64.6% | 22.7% | 37.2% | 25.2% | 26.8% | 30.7% | 40.3% | 32.4% | 3.0% | 13.0% | 51.8% |
| — | -481.3% | +10.7% | +16.4% | +263.9% | -8.1% | +151.9% | +43.0% | -68.4% | +50.7% | -340.8% | -26.1% | -7.6% | -22.2% | +797.9% | +136.4% | -22.2% | -10.3% | -93.4% | -63.7% | +70.2% | |
| Net Margin | 28.9% | -134.5% | 29.0% | 27.5% | 39.3% | 27.7% | 19.7% | 23.6% | 16.6% | 23.2% | -62.4% | 20.1% | 30.9% | 15.8% | 15.9% | 22.2% | 25.4% | 18.3% | 0.3% | 5.3% | 34.9% |
| — | -586.0% | +47.2% | +16.9% | +136.6% | +19.2% | +131.6% | +17.3% | -46.3% | +46.6% | -492.2% | -9.5% | +21.7% | -13.3% | +5415.3% | +320.9% | -27.3% | -25.4% | -98.9% | -74.8% | +538.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 40.7% | -59.7% | 8.8% | 9.9% | 14.9% | 10.1% | 6.9% | 9.5% | 6.8% | 9.1% | -20.7% | 6.4% | 10.1% | 5.0% | 4.8% | 7.8% | 8.7% | 5.7% | 0.1% | 1.8% | 12.6% |
| — | -688.7% | +27.9% | +4.5% | +117.1% | +12.0% | +133.1% | +49.2% | -31.9% | +82.1% | -532.8% | -18.1% | +16.1% | -12.8% | +5070.0% | +332.0% | -31.1% | -27.6% | -99.0% | -79.3% | +522.7% | |
| ROA | 14.4% | -19.9% | 3.5% | 3.7% | 5.3% | 3.5% | 2.3% | 3.1% | 2.3% | 2.9% | -7.0% | 2.3% | 3.5% | 1.7% | 1.6% | 2.6% | 2.9% | 1.8% | 0.0% | 0.6% | 3.8% |
| — | -668.5% | +53.9% | +18.2% | +130.5% | +19.0% | +132.4% | +36.8% | -33.7% | +74.6% | -536.0% | -12.0% | +22.6% | -7.4% | +5470.3% | +361.2% | -25.7% | -19.2% | -98.9% | -76.4% | +522.6% | |
| ROIC | 23.1% | -21.4% | 5.0% | 5.7% | 6.4% | 4.9% | 4.6% | 5.0% | 1.8% | 5.2% | -8.1% | 2.9% | 4.8% | 3.1% | 3.1% | 4.1% | 5.1% | 3.6% | 0.4% | 1.6% | 6.4% |
| — | -535.8% | +7.8% | +12.8% | +259.9% | -4.9% | +157.2% | +74.3% | -63.1% | +69.5% | -359.9% | -29.9% | -6.3% | -16.3% | +786.2% | +154.6% | -20.4% | -2.6% | -92.8% | -68.5% | +48.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.10 | 2.23 | 0.95 | 1.10 | 1.16 | 1.27 | 1.31 | 1.42 | 1.26 | 1.28 | 1.44 | 1.13 | 1.12 | 1.20 | 1.21 | 1.19 | 1.20 | 1.30 | 1.32 | 1.27 | 1.29 |
| — | +75.5% | -27.6% | -22.3% | -8.1% | -0.8% | -9.4% | +25.9% | +12.6% | +7.2% | +19.7% | -5.2% | -6.2% | -7.7% | -8.4% | -6.1% | -7.1% | -15.3% | -17.3% | -26.5% | -23.1% | |
| Debt / EBITDA | 1.72 | — | 6.77 | 6.79 | 6.22 | 7.88 | 8.51 | 8.69 | 14.73 | 7.00 | — | 11.16 | 7.55 | 10.76 | 10.76 | 9.03 | 7.50 | 10.26 | 36.30 | 18.10 | 6.34 |
| — | — | -20.4% | -21.9% | -57.8% | +12.7% | — | -22.1% | +95.0% | -35.0% | — | +23.6% | +0.7% | +4.8% | -70.3% | -50.1% | +18.3% | -5.9% | +304.7% | +77.4% | -49.0% | |
| Current Ratio | 1.55 | 1.27 | 1.97 | 1.55 | 1.45 | 1.32 | 1.37 | 1.60 | 1.26 | 1.14 | 1.08 | 1.43 | 1.34 | 1.02 | 1.28 | 1.29 | 1.30 | 1.43 | 1.48 | 1.27 | 1.37 |
| — | -3.8% | +43.7% | -2.8% | +15.3% | +15.1% | +26.9% | +12.0% | -5.8% | +11.7% | -15.6% | +11.0% | +2.9% | -28.4% | -13.4% | +1.0% | -4.8% | +4.8% | +7.9% | -9.3% | -58.0% | |
| Quick Ratio | 1.40 | 1.09 | 1.77 | 1.40 | 1.31 | 1.15 | 1.23 | 1.45 | 1.10 | 0.95 | 0.94 | 1.27 | 1.20 | 0.91 | 1.13 | 1.15 | 1.16 | 1.27 | 1.30 | 1.13 | 1.20 |
| — | -5.6% | +43.9% | -3.6% | +18.8% | +20.7% | +31.0% | +14.8% | -8.1% | +5.3% | -17.0% | +10.1% | +3.3% | -28.5% | -13.4% | +1.6% | -3.5% | +6.5% | +9.9% | -9.8% | -61.8% | |
| Interest Coverage | 10.57 | -40.51 | 9.80 | 9.15 | 15.22 | 10.56 | 7.34 | 9.70 | 5.02 | 9.66 | -16.66 | 7.56 | 10.99 | 7.90 | 6.65 | 9.99 | 11.62 | 7.21 | 0.36 | 4.19 | 14.75 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GILD stock.
Gilead Sciences, Inc.'s current P/E is 23.2x. The average P/E over the last 3 quarters is 16.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Gilead Sciences, Inc.'s current operating margin is 39.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Gilead Sciences, Inc.'s business trajectory between earnings reports.